Korean dental biotech company HysensBio to go public

Korean dental biotech company HysensBio to go public

HysensBio Co., a South Korean dental biotech company engaged in the development and manufacture of treatments for intractable dental diseases, is going public.

According to the investment banking industry, HysensBio recently filed for preliminary examination of an initial public offering (IPO) on the secondary Kosdaq market. The number of shares to be offered is 1.6 million, representing 13.5 percent of 10.34 million shares to be listed. The largest shareholder is Park Joo-cheol, chief executive officer of the company, who owns 30.16 percent of the shares. The lead manager of the IPO is Korea Investment & Securities Co.

In particular, the company is attracting strategic investment and establishing a joint venture with Orion Holdings Inc. to target overseas markets. In November last year, HysensBio established a joint venture, Orion Biologics, with Orion Holdings. In May, it also attracted a strategic investment of 2 billion won ($1.56 million) from Orion Holdings. The joint venture will use HysensBio’s technology to expand the business of dentin hypersensitivity toothpastes, whitening toothpastes, 에이스 치아보험 and chewing gums for people with dentin hypersensitivity. It is currently developing functional toothpastes for the Chinese and Southeast Asian markets and is also preparing for clinical trials for the Chinese market.

Solidus Investment Co., KB Investment Co., and CAPE Investment & Securities Co. participated in HysensBio’s recent pre-IPO worth 11.3 billion won. Existing investor DS Asset Management Co. also reinvested. The company is known to be valued at more than 100 billion won. Last year, HysensBio posted sales of 6 billion won and an operating loss of 3.5 billion won.

Leave a Reply

Your email address will not be published. Required fields are marked *